CPT 81259 HBA1/HBA2 Sequencing Reimbursement

CPT code 81259 represents full-gene sequencing of the alpha globin genes HBA1 and HBA2 to identify variants linked to alpha thalassemia and select structural hemoglobinopathies. This molecular diagnostic code matters nationally because sequencing of alpha globin genes guides diagnosis, carrier screening, and clinical management decisions for patients with microcytic anemia or suspected hemoglobin disorders. Access to accurate genetic diagnosis can affect treatment choices, family planning, and public health surveillance.

Key payers included in the analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find the clinical context for CPT code 81259, typical sites of service, and the primary service type. The publication outlines common billing modifiers associated with laboratory molecular testing and identifies areas where policy language and coverage criteria commonly affect test utilization and claims adjudication. It also provides benchmarking concepts and practical billing considerations for laboratories and billing staff. Data not provided in the input—such as specific ICD-10 pairings, payer-specific coverage policies, and associated taxonomies—are noted as unavailable in the input.

Billing Code Overview

CPT code 81259 describes the laboratory analysis of the full gene sequence for alpha globin 1 and alpha globin 2 (HBA1/HBA2) genes. This test is used to detect variants associated with alpha thalassemia and certain structural hemoglobinopathies by sequencing the entire coding region of both alpha globin genes.

Service Type: Molecular genetic testing / Laboratory sequencing

Typical Site of Service: Clinical molecular laboratory or reference genetic testing laboratory

Clinical Context

A 28-year-old pregnant woman of Southeast Asian descent presents to a maternal-fetal medicine clinic for prenatal screening after her partner’s carrier screen identified an alpha globin gene deletion. The obstetrician orders molecular sequencing of the alpha globin genes to evaluate the entire HBA1/HBA2 coding regions and detect point mutations, small insertions/deletions, and rare structural variants that can cause alpha thalassemia or structural hemoglobinopathies. Peripheral blood is drawn and sent to a reference molecular laboratory. The laboratory receives the sample, performs DNA extraction, and runs targeted next-generation sequencing or Sanger sequencing of the full HBA1 and HBA2 gene sequences. The lab analyst documents technical findings and generates a report for review by a board-certified molecular pathologist who issues the final interpreted report. Results are communicated to the ordering obstetrician and genetic counselor for reproductive risk discussion and potential partner testing.

Coding Specifications

Modifier	Description	When to Use
`26`	Professional component	Use when billing only the professional interpretation by the pathologist or laboratory director separate from the technical component.
`TC`	Technical component

Taxonomy Code	Specialty	Notes
207RP0000X	Clinical Pathology	Physicians who oversee molecular diagnostics and interpret sequencing results.
2080P0207X	Clinical Molecular Genetics	Specialists who perform test development and result interpretation for inherited hemoglobinopathies.
2080P0206X	Clinical Cytogenetics	Providers who may be involved when structural variants or deletions are suspected and cytogenetic correlation is needed.
207L00000X	Clinical Laboratory Director	Laboratory directors responsible for overall test validation and reporting.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`D56.3`	Alpha thalassemia	Primary indication for HBA1/HBA2 full gene sequencing to define mutations and guide counseling.
`D56.9`	Thalassemia, unspecified	Used when thalassemia is suspected but subtype not yet determined; sequencing clarifies alpha vs beta.
`D58.9`	Hereditary hemolytic anemia, unspecified	Sequencing may identify structural hemoglobin variants causing hemolysis.
`O35.3XX0`	Maternal care for (suspected) fetal chromosomal abnormality, unspecified trimester, not applicable or unspecified fetal status	Used when prenatal concern for fetal hemoglobinopathy requires parental molecular testing (note: select appropriate O35 subcode clinically).
`Z15.01`	Genetic susceptibility to sickle-cell disease and thalassemia	Carrier screening context where sequencing informs reproductive risk.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81256`	HBA1 (alpha globin 1) and HBA2 (alpha globin 2) gene analysis; common targeted mutation analysis (single variant)	Used when testing targets specific known common variants rather than full gene sequencing; may precede or follow full sequencing if a targeted panel is negative or confirmatory testing is needed.
`81257`	HBA1 and HBA2 gene analysis; duplication/deletion analysis by quantitative methods	Used when large deletions or gene copy number changes are suspected; complements full sequence analysis to detect deletions not identified by sequencing.
`81320`	Genotype analysis, globin genes; beta globin (HBB) sequencing	Performed when comprehensive hemoglobinopathy evaluation includes sequencing of beta globin genes alongside alpha globin testing.
`88237`	Flow cytometry for hemoglobin variants (qualitative)	Performed in clinical workflow to screen for abnormal hemoglobins prior to molecular sequencing to guide which genes to analyze.
`83020`	Hemoglobin electrophoresis, quantitative	Often performed prior to molecular testing to identify abnormal hemoglobin fractions and support molecular interpretation.

OpenPayer

Summary & Overview

CPT 81259: Full-Gene Sequencing of HBA1/HBA2 for Alpha Thalassemia